Source: Google NewsPublished on 2021-02-17
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- Top Parkinson’s Experts Join Inhibikase Therapeutics Scientific Advisory Board March 11, 2019 To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB). The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline includes prospective therapies developed from its proprietary Re-engineering Approach with Metabolism Preserved…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate - Yahoo Finance February 17, 2021 Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate Yahoo Finance
- Cerevel Therapeutics Initiates Phase 3 Program Testing Tavapadon for Improved Motor Function January 16, 2020 Cerevel Therapeutics announced its launch of a series of Phase 3 clinical trials to evaluate its investigational therapy tavapadon, designed to improve motor function in people with Parkinson’s disease. The company will conduct three 27-week trials to evaluate tavapadon’s efficacy, safety, and tolerability in fixed doses — TEMPO-1 (NCT04201093) — and flexible doses — TEMPO-2 (NCT04223193) and TEMPO-3 (not yet…
- Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021 - Benzinga February 10, 2021 Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021 Benzinga
- Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson's Disease - GlobeNewswire March 19, 2019 Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson's Disease GlobeNewswireATLANTA and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors ...
- Inhibikase Therapeutics, Inc. - Proactive Investors USA & Canada May 2, 2019 Inhibikase Therapeutics, Inc. Proactive Investors USA & CanadaInhibikase Therapeutics Inc President & CEO Milton Werner sat down with Proactive Investors at the ThinkEquity Conference in New York.
- Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and Amyotrophic Lateral Sclerosis | Small Molecules | News Channels - PipelineReview.com May 8, 2019 Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and Amyotrophic Lateral Sclerosis | Small Molecules | News Channels PipelineReview.comNeuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and ...
- How Medical Cannabis Eases HIV Symptoms, Reduces Disease Progression - Benzinga August 7, 2019 How Medical Cannabis Eases HIV Symptoms, Reduces Disease Progression BenzingaBy Tina Magrabi via WeedMaps News, provided exclusively to Benzinga Cannabis. Human Immunodeficiency Virus (HIV) may no longer be a death sentence, ...
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease - Benzinga March 18, 2019 Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease BenzingaSAN CARLOS, Calif., March 18, 2019 /PRNewswire/ -- Alkahest, Inc., a clinical-stage biotechnology company focused on developing transformative therapies to ...
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Inhibikase Therapeutics gets dosing underway in - Seeking Alpha February 17, 2021 Inhibikase Therapeutics gets dosing underway in Seeking Alpha
- Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering December 22, 2020 ATLANTA, Dec. 22, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public...
- Inhibikase Therapeutics Announces Closing of Initial Public Offering December 28, 2020 ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the closing of its...
- Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer January 4, 2021 ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, announced today that it has formed a partnership with Clintrex Research...
- Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference February 22, 2021 ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, today announced that it will present findings from its oral therapy studies for...
- 2019: Year in review December 31, 2019 In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
- Intec Shares Slammed As Advanced Parkinson's Disease Drug Combo Flunks Late-Stage Study - Benzinga July 22, 2019 Intec Shares Slammed As Advanced Parkinson's Disease Drug Combo Flunks Late-Stage Study BenzingaMicro-cap Intec Pharma Ltd (NASDAQ: NTEC) shares are plummeting on heavy volume Monday following a clinical trial readout from the company.